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ABSTRACT 
Tropicamide is an antimuscarinic drug used in eye disease. The niosomal vesicular drug delivery system facilitate the permeation of drug 
through the cornea because of the micron/nano size of vesicles containing drugs, which will increase the corneal penetration of drug, and 
increase the residence time of formulation in ocular cavity that result to increase the bioavailability of drug. Tropicamide loaded Niosomes by 
investigating the relationship between drug/Nonionic surfactant ratio were successfully prepared by thin film hydration method and compare 
the result of different grade of span used (20,40,60) with different ratio of cholesterol. niosomes were evaluated for partic le size ,drug 
entrapment efficiency, drug content ,corneal permeation study and in–vitro drug release. Respectively as a result the niosomes designed 
showed nearly spherical particles with a mean particle size 156.3nm. Niosomes prepared using cholesterol and span 60 in the ratio (1:1) f9 
shoed higher entrapment efficiency (84.35%) in-vitro drug release (94.02%) was optimized. 
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INTRODUCTION   
The drug delivery to the eyes is a difficult task for the 
formulation because the eye is protected by a series of 
complex defense mechanisms, which make it difficult to 
achieve an effective concentration of the drug at the target 
site of the eye. Traditional ophthalmic dosage forms include 
solutions, suspensions; ointments are still acceptable, such 
dosage forms are no longer sufficient to overcome the 
various ocular diseases like glaucoma due to poor 
bioavailability1. 
Marketed conventional preparations have many demerits, 
like poor absorption, permeation, retention time of drug in 
the ocular. The main objective of designing a ocular delivery 
is to achieve an maximum concentration of a drug at the 
target site for the longer time. Ocular retention time and loss 
of drug is based upon its physical-chemical properties as 
well as their ocular anatomy and physiology2.  
The many approaches have been used to enhance the 
retention time of drug in ocular cavity these are   2 
categories:  
The first one is depend on the use of controlled drug delivery 
systems, which provide the prolonged and continuous 
delivery of ophthalmic formulation.  
The second one involves enhance corneal drug absorption 
and reduced precorneal drug loss [3, 4]. 
Most commonly available conventional ophthalmic 
preparations are eye drops and ointments in market. But 
these formulations when administration into the eye are 
rapidly loss from corneal layer due to tear flow and 
nasolachrymal drainage. Only a small amount (10%) is 
available for its therapeutic effect resulting in frequent 
dosing is required. So attempt was take to overcome to these 
problems noval pharmaceutical ophthalmic formulation have 
been developed to release the drug in sustained and 
controlled manner to increase the ocular bioavailability5. 
Niosomes 
 Niosomes is a non-ionic surfactant-based liposome. 
Niosomes are formed with or without incorporation of 
cholesterol or lipids as an excipient.  Niosomes carry both 
water soluble & water insoluble drug its more penetrating 
capacity than other formulation like; suspension, emulsions. 
They are structurally similar to liposomes but it is more 
stable then liposome, however, the nonionic surfactants used 
to prepare niosomes make them more stable. 
Niosomes are microscopic-lamellar, spherical, unilamellar 
and multilamellar structures which are formed on the 
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admixture of non-ionic surfactant (span 20, span 40, span 
60) and cholesterol with subsequent hydration in aqueous 
media (distilled water).  
Drug delivery through novel formulation (niosomes) is one 
of the best approaches to achieve effective drug 
concentration.[5,6,7] 
 Advantages:[8,9] 
 Excellent reproducibility and feasible large scale 
production. 
 Niosomes are chemically stable, high entrapment 
efficiency and have long storage time instead of 
liposome.  
 Niosomes carry both hydrophilic and hydrophobic 
drugs. 
 They have high biocompatibility with biological 
systems & low toxicity because of their non-ionic 
nature. 
 Increased product stability of about 1 year in compare 
to liposome. 
 Niosomes improved (bioavailability & permiatiom) 
therapeutic performance. 
MATERIALS AND METHODS 
Materials 
Tropicamide was a gift sample from Bal pharma pvt. ltd. 
Span 20, Span 40 and span 60 were obtained from yerrow 
chem. Products All other solvents and reagents used for 
study were of analytical grade. 
Thin film hydration method 
Niosomes of ocular delivery are prepared by non-ionic 
surfactants because the irritation power of surfactants 
decreases in the following order: cationic >anionic > 
ampholytic > non-ionic. Niosomes of Tropicamide were 
prepared by thin film hydration method using non-ionic 
surfactants span 20, span40, span60 in different ratio with 
cholesterol as shown in Table.1. Accurately weighed quantity 
of surfactant and cholesterol in different molar ratios were 
weigh and dissolved in Chloroform: Methanol (2:1 v/v) 
solvent mixture and stirred until it gets completely dissolved. 
Then it was vortexed in a round bottomed flask at 
temperature 55 C to remove the solvent under reduced 
pressure in the rotary flask evaporator at 100 rpm for 30-40 
min. After evaporation, the surfactant and cholesterol 
formed a thin film on the inner sides of round bottom flask. 
Then the film was hydrated with aqueous phase containing 
the drug in 30 ml of phosphate buffer saline pH 7.4 for 30 
min at temperature 55ºC to obtain white dispersion of 
niosomes. The above white dispersion (Niosomes) was 
cooled in an ice bath and then using bath type sonicator 
sonicate for 20 minute. The resulted vesicles of niosomes 
were stored at 40C in a refrigerator for further studies.11 
Evaluation of Tropicamide Loaded Niosomes: 
Size analysis 
Fourier Transform Infrared Spectroscopy: 
It was important to check any kind of interaction between 
drug and excipient. It was done using Fourier Transformed 
Infrared Spectroscopy.IR spectra of pure Tropicamide and 
polymers were taken separately. Then to know if there is any 
interaction between drug and polymer, IR spectra of physical 
mixture of Tropicamide and polymers were taken in 
combination.[10]   
Particle size:9,10  
The average diameter and PDI of prepared batches of 
Tropicamide loaded niosomes were determined by photon 
correlation spectroscopy (PCS) using a zeta sizer (Malvern, 
Ver. 6.01) at a fixed angle at 25°C.Sample was diluted 10 
times with distilled water and then it was analyzed for 
particle size. The readings were recorded in triplicate and 
reported. 
Zeta potential  
The zeta potential can be measured by determination of the 
movement velocity of the particles in an electric field and the 
particle charge. The niosomes was diluted 10 times with 
distilled water and analyzed by zetasizer (Malvern, Ver. 
6.01).  
Drug content analysis:10,11  
The drug content was determined by dissolving the 1 ml of 
niosomes containing dispersed niosomes in methanol and 
continues stirring in mechanical stirrer for 30 minute to 
break the niosomal structure and release the entrapped 
drug. After suitable dilution with phosphate buffer pH 7.4, 
samples were analyzed spectrophotometrically using UV-
visible spectrophotometer (Shimadzu, UV-1800, Thane) at 
wavelength of 257 nm and drug content was determined. 
Drug entrapment efficiency: 
The drug entrapment efficiency (EE), which corresponds to 
the percentage of Tropicamide encapsulated within and 
absorbed on to the niosomes .was determined by measuring 
the concentration of free Tropicamide in the dispersion 
medium. 1.0 ml of Tropicamide loaded niosomes was diluted 
up to 10 ml with methanol and centrifuged at 14000 r.p.m 
for 45 minutes. Supernatant was then filtered by 0.2µ 
membrane filter and analyzed by UV-VIS spectroscopy at 256 
nm. 
% Entrapment efficiency= Entrapped amount of drug/Total 
amount of drug added ×100 
In-vitro release studies:  
In-vitro drug release from the formulation was studied by the 
diffusion cell. In-vitro release studies was done using  donor 
receiver compartment model using dialysis membrane 
soaked overnight in the receptor medium(simulated tear 
fluid, pH7.4).The diffusion medium was 100 ml of simulated 
tear fluid stirred at 100 rpm at (37ºC±0.5.ºC) One end of the 
diffusion tube was covered by a dialysis membrane. The 5 ml 
Niosomes formulations were filled in test tubes covered with 
a dialysis membrane and was placed such that it just touches 
the diffusion medium (STF) present in receptor 
compartment. The drug sample were withdrawn at the 
interval of0 .30 hour for the period of 12 hrs from diffusion 
medium and analyzed by a UV spectrophotometer at 257 nm 
using simulated tear fluid as a blank.  
Accelerated stability studies for the optimized 
Formulation: 
Stability of a pharmaceutical preparation can be defined as, 
“In a specific container/ closure system the capability of a 
particular formulation to remain within its physiochemical, 
microbilogical, therapeutic specification throughout the shelf 
life” Accelerated stability studies of the optimized 
formulation was carried out as per ICH guidelines , at 
refrigeration temperature by using stability chamber for 
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period of three month. Formulation was observed for 
viscosity, drug content and gel formulation ability.  
Vitro Drug Release Kinetics: 
In order to investigate the mechanism of release, the release 
data were analyzed with the following mathematical models: 
zero-order kinetic (Eq. 3), first-order kinetic (Eq. 4) and 
Higuchi kinetic (Eq. 5): 
Zero-order model: 
Drug dissolution from the dosage forms that do not 
disaggregate and release out the drug slowly can be 
represented. by this  
Qt =Q0+ K0 t                           (3) 
Where  
Qt – The Qt   is content of drug dissolved in time t,  
Qo-The Qo  is initial content  of drug in the solution (most 
times, Qo = 0)   
K0- The K0 is the zero order release constant.  Its unit is 
{concentration/time}. 
The in- vitro drug release studies were plotted between 
cumulative amount of drug released and time. 
First order model: 
This first order model has also been used to determine 
absorption or elimination process of drugs, although it is 
difficult to understand this mechanism absorption and 
elimination on the behalf of theoretical basis. The  first order 
kinetics can be expressed by the equation: 
Log Qt = Log Q0 -   K1 t          (4) 
                                 2.303 
Wher e: 
 Q0 = initial concentration of drug, 
 K1 = first order rate constant, and 
 T = time.  
The graph was plotted between log cumulative percentages 
of drug remaining or time which would yield a straight line 
with a slope of [-K/2.303] 
Higuchi model 
The Higuchi model is based on the hypotheses accordingly 
this model expression is given by the equation: it is used to 
measure release rate of formulation 
Q = KH t1/2                                (5) 
Where,  
KH: is the Higuchi dissolution constant. 
t1/2= square root of time  
The data obtained were plotted as cumulative percentage 
drug release vr. Square root of time. 
Korsmeyer-Peppas model 
The first 60% drug release data were fitted in Korsmeyern 
Peppas model.  
{Mt / M∞ = Ktn  }                       (6) 
Where: 
 Mt / M∞ = fraction of drug released at time t,  
K = release rate constant. 
 n = release exponent.  
The n value is used to characterize different release for 
cylindrical shaped matrices.  
In this model, the value of n characterizes the release 
mechanism of drug as described in Table. To study the 
release kinetics, data obtained from in vitro drug release 
studies were plotted as log cumulative percentage drug 
release versus log time. 
RESULTS AND DISCUSSION  
Compatibility studies of Tropicamide and non-ionic 
surfactants: 
Infra red spectra of pure drug Tropicamide as well as drug 
with non ionic surfactant shows characteristic absorption 
peaks shown in Figure No. 1 All the characteristic peaks of 
Tropicamide were present in spectra thus indicating 
compatibility between drug and non- ionic surfactants. It 
shows that there was no significant change in the drug. 
Solubility:   
Solubility result was found to be Tropicamide freely soluble 
in acetone, ethanol, methanol and phosphate buffer (pH 7.4). 
Appearance: 
Appearance of formulation is important parameter for 
ophthalmic drug delivery. All formulations were found to be 
turbid shown in Figure No.9 
pH: 
pH values for all the formulations was found to be 
satisfactory in the range of 7.0-7.4 as tabulated in Table No. 9 
The pH was within acceptable range and hence would not 
cause any irritation upon administration of the formulations. 
Particle size and Zeta potential analysis: 
Particle size analysis: 
The particle size analysis was performed for optimized 
formulation by using Malvern zeta sizer.  
Zeta size of particle F9 was found 156.   
Zeta potential:  
Zeta potential are performed optimized formulation of 
Tropicamide loaded niosomes batch no F9 were shown in 
table no. Zeta potential of particles of F9 span 60 batch was 
found in the range of +16m. 
Drug Entrappment: 
Drug entrapment efficiency of niosomes formulations are 
shown in table no. 8 among the niosomes formulations 
highest drug entrapment efficiency 84.66% was observed 
with formulation F9 and lowest drug entrapment efficiency 
78.7% was observed with formulation F4. As increased 
concentration of span and decreased concentration of 
cholesterol there is a increased entrapment efficiency of the 
niosomal formulation. span 60 shows more entrapment 
efficiency. 
Drug content: 
Drug content formulations are shown in table no.8 Among 
the niosomal formulations highest drug content was 
observed 96.34% of F11 formulation and the lowest drug 
content was observed 50.97% of F6 formulation. As the 
increased non-ionic surfactant concentration there is 
increased drug content of niosomal formulations. 
Joshi et al                                                                                                      Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):69-75 
ISSN: 2250-1177                                                                                  [72]                                                                                 CODEN (USA): JDDTAO 
In-vitro drug release study: 
In-vitro drug release from the formulation was studied for all 
formulations. The medium consist 900 ml of Phosphate 
buffer pH 7.4 stirred at 50 rpm at 37˚C±5˚C. The drug release 
of a formulation shows in table no.12. 
In-vitro drug release kinetics: 
The drug release kinetics of that formulation best fitted in 
the Peppas - Korsmeyer model and the R2 value was found to 
be 0.98. The drug release kinetic of a formulation shows in 
table no.13. 
Accelerated stability studies for the optimized 
formulation: 
Optimized formulation (F9) was evaluated for the stability 
studies at refrigeration temperature. Result revealed that no 
change were observed in visual appearance, clarity, pH, drug 
content, drug entrapment was determined at periodical 
interval for each formulation which was found satisfactory. 
The figure show in table no.14. 
 
 
Formulation of Tropicamide Niosomes composition of Niosome: 
Table-1 Niosomes with varying Cholesterol: Surfactant Molar Ratio 
S.NO. Drug(mg) Cholesterol(mg) Span 20(mg) Solvent(chloroform:methanol) (2:1) 
1 50 100 100 15 
2 50 95 105 15 
3 50 90 110 15 
4 50 85 115 15 
 
Table-2 Niosomes with varying Cholesterol : Surfactant Molar Ratio(span 40) 
S.NO. Drug(mg) Cholesterol(mg) Span 40(mg) Solvent(chloroform:methanol)   (2:1) 
1 50 100 100 15 
2 50 95 105 15 
3 50 90 110 15 
4 50 85 115 15 
 
Table-3 Niosomes with varying Cholesterol: Surfactant Molar Ratio(span 60) 
S.NO. Drug(mg) Cholesterol(mg) Span 60(mg) Solvent(chloroform:methanol) (2:1) 
1 50 100 100 15 
2 50 95 105 15 
3 50 90 110 15 
4 50 85 115 15 
 
Table 4: Determination of drug entrapment and Drug 
content 
Formulation % Drug 
Entrapment 
% Drug 
Content 
F1(span20) 84 78 
F2(span20) 82.88 68.53 
F3(span20) 80.71 66.34 
F4(span20) 78.75 78.77 
F5(span40) 84.66 90.24 
F6(span40) 82.95 50.97 
F7(span40) 83.22 72.19 
F8(span40) 83.68 95.85 
F9(span60) 84.35 95.36 
F10(span60) 83.22 86.3 
F11(span60) 82.24 96.34 
F12(span60)  82.25 91.70 
Table 5: Determination of Clarity and pH 
Formulation 
 
visual appearance 
 
pH 
F1 Clear 7.233 
F2 Clear 7.2 
F3 Clear 7.066 
F4 Clear 7.166 
F5 Clear 7.266 
F6 Clear 7.233 
F7 Clear 7.133 
F8 Clear 7.166 
F9 Clear 7.233 
F10 Clear 7.366 
F11 Clear 7.2 
F12 Clear 7.0333 
 
Table 6: Particle size and zeta potential analysis 
S.no. Optimized 
formulation 
Mean particle 
size(nm) 
Zeta potential(mV) Pdi 
1. F9 156.82 16 0.277 
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Table 7: Pure Drug Dissolution 
Time %cdr 
0.5 0.391899 
1 6.14987 
2 11.388 
3 17.14923 
4 23.19031 
5 27.40523 
6 37.81308 
7 41.74769 
8 50.90769 
9 54.55846 
10 58.17846 
11 62.90615 
12 74.28615 
 
Table 8: In-vitro Drug release study F9 (SPAN60) 
Formulation 
Time % CDR 
0.5 0.159494 
1 3.04704 
2 5.167692 
3 8.336308 
4 12.31385 
5 18.34508 
6 27.68308 
7 35.04554 
8 51.97846 
9 64.81077 
10 80.11231 
11 88.78154 
12 96.30615 
 
Table9: F14 Accelerated stability study of optimized formulation F9 
Parameter 15 days 30 days  45 days 
pH 7.1 7.1 7.2 
Drug entrapment 84 83.48 83.20 
Viscosity 5.34 5.28 5.11 
Dug content  94.21 94.033 93.98 
 
 
Figure 1: IR spectra of pure drug 
 
Figure 2: size distribution report 
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Figure 3: Zeta potential report 
 
 
Figure 4: % CDR of Tropicamide 
 
Figure 5: % CDR of pure drug and optimized formulation 
{Comparison of drug release between optimized drug and pure drug 
(pd-pure drug )(od-optimized drug)} 
 
Fig: 6 Zero order release kinetics of optimized batch F9 
CONCLUSION 
In the last couple of years, continuous research has been 
going on for better delivery for ocular with the aim of more 
localized drug delivery and minimization of dosing 
frequency. An ophthalmic delivery system should preferably 
release the drug at a controlled rate to prolong the effect in 
reducing IOP and should be non toxic and comfortable for 
patient use. Tropicamide loaded Niosomes can be prepared 
by hand shaking method  with Span 20,40,60 and cholesterol 
in the different ratio. In vitro release of Tropicamide from 
niosomes was very slow when compared to the release from 
Tropicamide solution. Our findings have shown that higher 
EE% of (84.22%) was obtained from niosomes prepared 
using Span 60/CH at F9 molar ratio with particle size 
diameter of 156.82 nm. In conclusion, niosomes could be a 
promising delivery system for Tropicamide with improved 
ocular bioavailability and prolonged drug release profiles. 
ACKNOWLEDGEMENTS 
The authors wish to thank Dr. D.K. Sharma (Principal), A.K. 
Singh (HOD) and Devsthali Vidyapeeth College of Pharmacy, 
Lalpur, Rudrapur, for their kind support and encouragement 
me to carry out this work. 
REFREENCES 
1. Bharath S. Sustained ophthalmic delivery of Ofloxacin from an 
ion activated in situ-gelling system.Pak. J. Pharm. Sci. 2009; 
22:2. 
2. Macha S, Mitra AK. Ophthalmic drug delivery systems; second 
edition revised and expanded. Chapter 1 Overview of Ocular 
Drug Delivery. p 1-3.  
3. Sasaki H, Yamamura K, Nishida K, Nakamurat J, Ichikawa M. 
Delivery of drugs to the eye by topical application.1996; 
15(2):553- 620.  
4. Sathyavathi V, Sathali AH, Ilavarasan R, Sangeetha T. 
Formulation and Evaluation of Niosomal in-situ Gel Ocular 
Delivery System of BrimonidineTartarate. International 
Journal of Life Science and Pharma Research, 2012; 2(1):82.  
5. Chien YW. Novel drug delivery systems. 2nd ed.New York: 
Marcel Dekker; 1992. 
6. Gumbhir-Shah K, Cevallos WH, DeCleene SA, Halstenson CE, 
Korth-Bradley JM.Absolute bioavailability of Bromfenac in 
humans; Ann Pharmacother 1997; 31(4):395-9. 
7. Fang JY, Yu SY, Wu PC, Huang YB, Tsai YH. In vitro skin 
permeation of estradiol from various proniosome 
formulations. Int J Pharm, 2001; 215 91–99.  
8.  Robinson JR. Bioadhesive-based dosage forms: the next 
generation. J. Pharm. Sci. 2000; 89:850-66. 
0
20
40
60
80
0 5 10 15
%
cd
r 
time(hrs) 
% CDR of Tropicamide 
%cdr
0
20
40
60
80
100
0 2 4 6 8 10 12
%cdr pd
%cdr od
Comparison of drug release between optimized drug and pure drug  
y = 0.1299x + 3.9756 
R² = 0.958 
-20
0
20
40
60
80
100
0 200 400 600 800
%
C
D
R
 
Time 
zero order release 
Joshi et al                                                                                                      Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):69-75 
ISSN: 2250-1177                                                                                  [75]                                                                                 CODEN (USA): JDDTAO 
9. Deepika Aggarwal, InduKaur P. Improved pharmacodynamics 
of timolol maleate from a mucoadhesive niosomal ophthalmic 
drug delivery system. Int J Pharm. 2005; 290:155. 
10. Gautam Seema, Singh Arun Kumar, Bhardwaj Manoj.  
Development and evaluation of curcumin loaded nanosponges 
for colon drug delivery system.wjpr.2015; 4(5):1650-1666. 
11. Khandare J N, Jiwandas Bobade Hemant, Uppalritu. 
Preparation and evaluation of nimusalide niosomes for topical 
application. Indian Drugs. 2001; 38(4):197. 
12. Nagarsenker MS, Londhe VY, Nadkarni GD. Preparation and 
evaluation of liposomal formulations of tropicamide for ocular 
delivery. International journal of pharmaceutics. 1999; 
190(1):63-71.  
13. Swamy N.G.N, and Abbas Z.niosomes, Emerging colloidal 
carriers as Ocular Drug Delivery systems; Indian drugs 2013; 
50(04). 
14. Pate, N.M, Soniwala M.M. Influence of release enhancer on 
release of Venlafaxine HCL from glyceryl behenate matrix 
tablet. Indian Drugs, 2008; 45(2):104-15.  
15. Vyas SP, Khar RK. Controlled drug delivery: Concepts and 
advances. 1st ed. Delhi: Vallabh Prakashan; 2002 p.392.  
16. Vyshnavi V, Indira  S, Srinivas p, Formulation and Evaluation 
of Nasal Niosomal in situ Gels of Loratadine, ijpspr, Issn: 0975-
248. 
17. Gupta A.K Madan, S. Majumdar, D.k., & Maitra, A, Ketorolac 
entrapped in polymeric micelles: Preparation, 
characterization and ocular anti-inflamatory studies, 
International Journal of Pharmaceutics, 2000; 209:1-14.  
18. Grit M, Crommelin D. J, “Chemical stability of liposomes. 
Implications for their physical stability ˮ, Chem Phys Lipids 
1993; 64:3–18. 
 
 
 
 
